Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting
02 juil. 2024 08h00 HE
|
Bionano Genomics
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the...
Gene Therapy R&D Market Report 2024-2034 - Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments and a Promising Pipeline Reshaping Medicine's Future
01 juil. 2024 10h10 HE
|
Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Gene Therapy R&D Market is...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
01 juil. 2024 07h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Research 2023-2031: Stringent Regulatory Requirements, Growing Adoption of Personalized Medicine, Competition to Intensify
27 juin 2024 06h23 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key...
Global Cell and Gene Therapy CRO Market Research 2024-2035: Over 105 CROs Drive Innovations with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
26 juin 2024 06h37 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21 juin 2024 07h00 HE
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
21 juin 2024 06h05 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...
CRISPR and Cas Genes Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F
20 juin 2024 07h24 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F" report has been added to ...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
20 juin 2024 06h30 HE
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Europe Cell & Gene Therapy Market Insights 2024-2029: Rising use of CGT Products for Disease Care, Funding Support in Europe for CGTs
20 juin 2024 04h06 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Europe Cell & Gene Therapy Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Europe Cell &...